ASAP1-IT1

Summary

ASAP1-IT1 (ASAP1 intronic transcript 1, HGNC:24998) is a long non-coding RNA gene on chromosome 8q24.21.

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24998
Approved symbol	ASAP1-IT1
Name	ASAP1 intronic transcript 1
Location	8q24.21
Locus type	RNA, long non-coding
Status	Approved
Aliases	HSPC054, NCRNA00050, ASAP1IT, ASAP1-IT
Entrez	29065
RNAcentral	URS000075BE71 — lncRNA, 1179 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

None — 0 exons

Expression profiles

Top tissues by expression

0 total, by Bgee expression score (0-100, higher = more expressed):

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 2)

• Interference on ASAP1-IT1 expression could inhibit the proliferation of NSCLC cells, while the transwell experiment showed that the interference on ASAP1-IT1 expression could block the migration and invasion ability of NSCLC cells. ASAP1-IT1 could regulate the biological behaviors of NSCLC cells through phosphatase and tensin homolog deleted on chromosome ten (PTEN)/serine-threonine kinase (AKT) pathway. (PMID:29364481)
• ASAP1-IT1 could positively modulate Smo and Gli1 in Cholangiocarcinoma. (PMID:29653361)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Canonical reviewed UniProt: None (reviewed: )

All UniProt accessions (0):

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1001815501 (8:130297042 G>A,T), RS1001899909 (8:130296766 A>G), RS1002182786 (8:130297252 C>T), RS1002411091 (8:130298123 G>A), RS1002549517 (8:130298189 C>G), RS1002766972 (8:130298396 A>G), RS1002976394 (8:130295778 ATTT>A,ATT,ATTTT), RS1003894679 (8:130297285 G>A), RS1005447648 (8:130295708 C>T), RS1005894461 (8:130295488 C>T), RS1006351686 (8:130296082 T>C), RS1006633563 (8:130296104 T>C), RS1007930669 (8:130297804 G>C), RS1008302043 (8:130297586 C>A,T), RS1008334569 (8:130297294 C>A,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, increases expression	2
sodium arsenite	increases expression, increases stability	2
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Vorinostat	affects cotreatment, increases expression	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression	1
Valproic Acid	increases expression	1
Zinc	increases expression	1
Cyclosporine	increases expression	1
Cadmium Chloride	increases expression	1
beta-Naphthoflavone	increases expression	1
Copper Sulfate	increases expression	1
Lactic Acid	increases expression	1
Particulate Matter	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.